Table 3. Univariate and multivariate analysis between clinicopathological factors and RFS.
| Characteristics | Initial treatment | Repeated treatment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Univariate analysis | Multivariate analysis | No. | Univariate analysis | Multivariate analysis | ||||||
| Median RFS (95% CI) | p-value | HR (95% CI) | p-value | Median RFS (95% CI) | p-value | HR (95% CI) | p-value | ||||
| Age (yr) | ≥35 | 82 | 60.3 (25.1–95.5) | n.s. | - | 25 | 10.9 (9.8–14.9) | n.s. | - | ||
| <35 | 69 | 26.7 (14.8–38.7) | 37 | 16.3 (10.0–22.6) | |||||||
| BMI (kg/m2) | ≥25 | 36 | 26.8 (11.8–41.8) | n.s. | - | 17 | 16.3 (6.1–26.6) | n.s. | - | ||
| <25 | 112 | 45.1 (14.8–75.2) | 45 | 12.8 (9.7–15.9) | |||||||
| PCO | + | 38 | 26.7 (1.9–51.6) | 0.040 | - | 20 | 16.6 (6.1–27.2) | n.s. | - | ||
| − | 113 | 48.8 (6.7–90.8) | 42 | 12.8 (10.8–14.8) | |||||||
| Hyperprolactinemia | + | 17 | 40.3 (0–82.6) | n.s. | - | 9 | 11.6 (6.2–19.4) | n.s. | - | ||
| − | 61 | 12.4 (3.3–21.5) | 37 | 16.3 (8.5–24.1) | |||||||
| Family history of cancer | + | 51 | 13.8 (6.0–21.7) | 0.010 | 1.9 (1.1–3.2) | 0.040 | 28 | 11.0 (7.3–14.6) | n.s. | - | |
| − | 98 | 48.8 (24.0–73.6) | 34 | 16.6 (8.1–25.1) | |||||||
| Histological type | G1 | 87 | 21.4 (9.4–33.5) | <0.010 | 2.1 (1.1–3.7) | 0.020 | 43 | 11.6 (7.9–15.4) | n.s. | - | |
| AEH | 64 | - | 19 | 25.0 (3.1–46.9) | |||||||
| Initial TTD (mo) | ≥6 | 51 | 20.3 (12.3–28.3) | 0.020 | - | 27 | 10.9 (8.6–13.1) | n.s. | - | ||
| <6 | 100 | 60.4 (13.3–107.4) | 35 | 16.3 (7.8–24.8) | |||||||
| 2nd TTD (mo) | ≥6 | - | 18 | 8.8 (6.8–10.8) | n.s. | - | |||||
| <6 | - | 44 | 16.3 (10.3–22.4) | ||||||||
AEH, atypical endometrial hyperplasia; BMI, body mass index; CI, confidence interval; G1, grade 1 endometrioid carcinoma; HR, hazard ratio; n.s., not significant; PCO, polycystic ovary; RFS, recurrence-free survival; TTD, time-to-tumor disappearance.